Autenrieth M, Nawroth R, Semmlack S, Gschwend J E, Retz M
Urologische Klinik und Poliklinik, Klinikum rechts der Isar, Technische Universität München, München, Deutschland.
Urologe A. 2008 Sep;47(9):1157-61. doi: 10.1007/s00120-008-1829-8.
Detection of metastases in lymph nodes is an important prognostic factor for progression-free survival in bladder cancer patients. Patients undergoing radical cystectomy with pelvic lymphadenectomy are randomized in the LEA study (AUO AB 25/02) into two groups receiving standard (obturator and external nodes) or extended lymphadenectomy (complete pelvic nodes up to the inferior mesenteric artery).The aim of this study is the detection of lymph node metastases that are not identified with classic pathological methods using RT-PCR as a highly sensitive and specific method. For detection of occult disseminated tumor cells we analyze the expression of the tumor markers cytokeratin 20 (CK-20), uroplakin II (UP II), mucin 2 (MUC2), and mucin 7 (MUC7).We examined 315 lymph nodes from 19 cystectomy patients for the expression of CK-20. In 93 lymph nodes CK-20 expression was detected whereas only 18 lymph nodes were histopathologically positive. More than one third of CK-20-positive lymph node metastases were located outside the standard lymphadenectomy field. We did not detect any skip lesions. Follow-up data will validate if there is a correlation between detection of occult disseminated tumor cells and progression-free survival.
检测淋巴结转移是膀胱癌患者无进展生存期的一个重要预后因素。在LEA研究(AUO AB 25/02)中,接受根治性膀胱切除术及盆腔淋巴结清扫术的患者被随机分为两组,分别接受标准(闭孔和外侧淋巴结)或扩大淋巴结清扫术(清扫至肠系膜下动脉水平的完整盆腔淋巴结)。本研究的目的是使用RT-PCR这种高度敏感和特异的方法,检测经典病理方法无法识别的淋巴结转移。为了检测隐匿性播散肿瘤细胞,我们分析肿瘤标志物细胞角蛋白20(CK-20)、尿路上皮蛋白II(UP II)、粘蛋白2(MUC2)和粘蛋白7(MUC7)的表达。我们检测了19例膀胱切除患者的315个淋巴结中CK-20的表达。在93个淋巴结中检测到CK-20表达,而组织病理学阳性的淋巴结只有18个。超过三分之一的CK-20阳性淋巴结转移位于标准淋巴结清扫范围之外。我们未检测到任何跳跃性病变。随访数据将验证隐匿性播散肿瘤细胞的检测与无进展生存期之间是否存在相关性。